Description

Product Details

INGREDIENTS PER CAPSULE
MK677 30MG

DOSAGE: TAKE 1 CAPSULE A DAY BEFORE OR AFTER FOOD
CONTENTS: 30 Capsules 1 month supply
MP GROWTH CAN BE TAKEN ALL YEAR ROUND

Ibutamoren is an experimental substance which binds to the same receptors as ghrelin, a natural growth hormone secreted by enteroendocrine cells. Because it mimics this hormone so effectively, Ibutamoren is said to be a ghrelin receptor antagonist. Its anabolising, neuro-protective, lipolytic and anti-ageing properties are currently attracting significant scientific interest and are the subject of extensive investigation.

What Ibutamoren's effects?

In the body, MK-677 binds to ghrelin receptors on the surfaces of cells. This triggers a series of chain reactions including increased secretion of several hormones such as growth hormone (GH) and insulin-like growth factor (IGF-1).
These chain reactions are normally triggered by the action of ghrelin, a peptide hormone primarily released by endocrine cells in the intestines and stomach (1). Ghrelin has various physiological effects such as regulation of appetite (2) and adipose tissue (3), as well as of carbohydrate and energy metabolism (4). Recent studies have also demonstrated its role in cognitive function (5-6).
By mimicking ghrelin, MK-677 thus produces significant physiological benefits:
• it boosts muscle growth and strength, by increasing lean body mass (bigger muscles, increased muscle mass, prevention of loss of muscle during weight loss, etc) (7-10), without adding fat mass.
• it combats the muscle-wasting typically seen in older people or those temporarily incapacitated (with hip fractures, for example (11).
• it boosts bone density and renewal (by increasing levels of osteocalcin) (12).
• it improves sleep quality and duration (13). The rises in levels of certain hormones (in particular growth hormone and prolactin) appear to increase the duration of stage 4 sleep (the deepest of the sleep cycle) as well as that of rapid eye movement (REM), part of paradoxical sleep (14).
• it combats cellular ageing, primarily by compensating for decreased levels of growth hormone.
• it has potential nootropic effects
• it promotes faster wound-healing and recovery (15-16) as well as increased tolerance to exercise (17-18).
• it increases lipolysis (fat breakdown) (19).
• it reduces nitrogenous waste (20).
• it lowers blood levels of LDL-cholesterol.

These potential effects are the result of Ibutamoren's principal action of directly increasing circulating levels of IGF-1, a peptide hormone responsible for boosting protein synthesis and promoting overall tissue growth.

Clinical trials are continuing in order to identify any potential side effects, with a view to potentially authorising its sale for human consumption. Studies conducted so far have demonstrated slight increases in blood pressure, glycated haemoglobin and appetite (21). They have also shown that were it to be authorised for human consumption, it would be contraindicated for those with a history of congestive heart failure, especially elderly individuals. In any case, monitoring blood parameters would be essential, and it would only be possible to recommend those products with rigorously-controlled purity.

Who might benefit from Ibutamoren?

Currently, Ibutamoren is still at the stage of pre-clinical testing. It is therefore available solely for research purposes and is not approved for human consumption. However, its physiological effects and therapeutic potential mean that certain groups of people may be interested in monitoring developments in its research:
• those seeking improved sports performance and greater tolerance to exercise.
• those looking to boost their muscle mass and strength
• those recovering from physical injury
• those deficient in growth hormone
• those who've suffered muscle wasting or bone loss
• those who want to slow down the ageing process.

How does it differ from anabolic steroids?

Like MK-677, anabolic steroids produce an increase in muscle mass and physical strength, but that's where the similarity ends. Anabolic steroids are fatty acids which bind to 'androgen receptors' and trigger the expression of a number of target genes. This interaction causes anabolic effects, as well as a number of unintended consequences, such as a significant increase in virilisation (hairiness, growth in vocal cords, increased risk of baldness), a halt in natural production of sex hormones, an increase in LDL cholesterol, a rise in blood pressure and the development of problematic structural changes in heart ventricles. These unwelcome effects are damaging to the bodybuilding enthusiasts and elite athletes who use them.

Scientific studies show that MK-677 does not cause any side-effects. Depending on the results of the latest clinical trials, it could, in the years to come, constitute a safer alternative to anabolic steroids and a more effective one than growth hormone-releasing peptides (GHRPs), the bioavailability and half-life of which remain very low.

Ibutamoren thus appears to be an innovative and credible alternative for stimulating growth hormone secretion. It is already benefiting from sound clinical trials and produces far fewer side-effects than the substances it closely resembles, such as anabolic steroids and GHRPs.

Note: This product is for research purposes only. It is not approved for human consumption.

Written: October 2018.

References
1. Ariyasu, H.; Takaya, K.; Tagami, T.; Ogawa, Y.; Hosoda, K.; Akamizu, T.; Suda, M.; Koh, T.; Natsui, K.; Toyooka, S.; et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 2001, 86, 4753-4758.

2. Bowers CY, Momany F, Reynolds GA, et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1980; 106:663-667.

3. Bowers CY, Momany FA, Reynolds GA, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-1545.

4. Bowers CY. History to the discovery of ghrelin. Methods Enzymol 2012;514:3-32.

5. Gahete, M.D.; Cordoba-Chacon, J.; Kineman, R.D.; Luque, R.M.; Castano, J.P. Role of ghrelin system in neuroprotection and cognitive functions: Implications in Alzheimer's disease. Peptides 2011, 32, 2225-2228.

6. Kim, C.; Kim, S.; Park, S. Neurogenic Effects of Ghrelin on the Hippocampus. Int. J. Mol. Sci. 2017, 18.

7. Binnerts A, Swart GR, Wilson JH, et al. The effect of growth hormone administration
in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992;37:79-87.

8. Snel YE, Doerga ME, Brummer RJ, et al. Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy. Eur J Endocrinol 1995; 133:445-450.

9. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149:601-611.

10. Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998; 83:362-369.

11. Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998; 83:362-369.

12. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Min Res 1999; 14:1182-1188.

13. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK- 677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997;66:278-286.

14. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK- 677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997;66:278-286.

15. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004;52:516-
523.

16. Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-189.

17. Jorgensen JO, Pedersen SA, Thuesen L, et al. Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocinol 1991;125:449-453.

18. Whitehead HM, Boreham C, Mcllrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross- over study. Clin Endocrinol 1992;36:45-52.

19. Melmed S. Physiology of growth hormone. In: Rose BD, ed. UpToDate; 2008; Waltham, MA.

20. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998;83:320-325.

21. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008;71:1702-1708.

DISCLOSURE:
•The materials for sale are intended for laboratory and research use only.
•They are not for human consumption.
•They are not for use as food, additives, drugs, cosmetics, household chemical or other inappropriate applications.
•You must be at least 18 years of age to purchase and use this product.
•This product is not intended to diagnose, treat, cure or prevent any disease.